Therapeutic angiogenesis: controlled delivery of angiogenic factors.
Therapeutic angiogenesis: controlled delivery of angiogenic factors.
复制标题
DOI：
10.4155/tde.12.50
复制
发表时间：
2012-06
影响因子：
4.2
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Chu H;Wang Y
治疗性血管生成旨在通过从现有血管中生成新血管来治疗缺血性疾病。它依赖于外源性因子的传递来刺激新血管的形成。目前使用基因、蛋白质和细胞的策略已经在动物模型中证明了有效性。然而，由于各种原因，这三种方法中的任何一种的临床翻译都证明是具有挑战性的。根据累积的试验，血管生成因子的管理通常被认为是安全的，并且提供现成的可用性。然而，在治疗性血管生成成为一种真正的人类疗法之前，还有许多障碍需要克服。本文将重点介绍基于蛋白质的治疗性血管生成，简要回顾最近的进展，并检查关键挑战。我们将讨论在促进血管生成中被广泛应用的生长因子，并比较它们的靶点和功能。最后，由于大量注射游离蛋白通常会导致不良的结果，我们将重点关注蛋白质的控制释放。
Therapeutic angiogenesis aims at treating ischemic diseases by generating new blood vessels from existing vasculature. It relies on delivery of exogenous factors to stimulate neovasculature formation. Current strategies using genes, proteins and cells have demonstrated efficacy in animal models. However, clinical translation of any of the three approaches has proved to be challenging for various reasons. Administration of angiogenic factors is generally considered safe, according to accumulated trials, and offers off-the-shelf availability. However, many hurdles must be overcome before therapeutic angiogenesis can become a true human therapy. This article will highlight protein-based therapeutic angiogenesis, concisely review recent progress and examine critical challenges. We will discuss growth factors that have been widely utilized in promoting angiogenesis and compare their targets and functions. Lastly, since bolus injection of free proteins usually result in poor outcomes, we will focus on controlled release of proteins.